<DOC>
	<DOCNO>NCT00642941</DOCNO>
	<brief_summary>This study evaluate efficacy safety R1507 participant recurrent refractory sarcoma . Eight cohort sarcoma participant study parallel . Cohort 1 : Ewing 's sarcoma primary cohort define participant relapse less equal ( &lt; = ) 24 month diagnosis , receive least two prior chemotherapy program unresectable . Cohort 2 : Ewing 's sarcoma non-primary ( secondary ) cohort define participant relapse great equal ( &gt; = ) 24 month diagnosis receive one prior chemotherapy program . Cohort 3 : Expanded Ewing 's sarcoma define participant recurrent relapse regardless prior number salvage regimens regardless time relapse . Cohort 4 : participant osteosarcoma . Cohort 5 : Participants synovial sarcoma . Cohort 6 : Participants rhabdomyosarcoma Cohort 7 : Participants alveolar soft part sarcoma ( 7a ) , desmoplastic small round cell tumor ( 7b ) , extraskeletal myxoid chondrosarcoma ( 7c ) , clear cell sarcoma ( 7d ) , myxoid liposarcoma ( 7e ) . Cohort 8 : Participants unspecified sarcoma diagnosis . Participants expand Ewing 's sarcoma Cohort 3 receive 27 milligram ( mg ) /kilogram ( kg ) every 3 week intravenously ( IV ) . All participant receive R1507 9 mg/kg IV weekly . The anticipated time study treatment disease progression unacceptable adverse event , withdrawal death .</brief_summary>
	<brief_title>A Study R1507 Participants With Recurrent Refractory Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>progressive , recurrent refractory Ewing 's sarcoma , recurrent refractory osteosarcoma , synovial sarcoma , rhabdomyosarcoma , sarcoma follow subtypes : alveolar soft part sarcoma , desmoplastic small round cell tumor , extraskeletal myxoid chondrosarcoma , clear cell sarcoma myxoid liposarcoma ; Cohort 3 : age must &gt; = 2 &lt; = 21 year clinically significant unrelated systemic illness would compromise participant 's ability tolerate investigational agent , interfere study procedure result ; know hypersensitivity component R1507 prior hypersensitivity reaction monoclonal antibody ; treatment ( within past 2 week ) pharmacologic dos corticosteroid immunosuppressive agent ; current prior therapy insulinlike growth factor ( IGF ) inhibitor ( monoclonal specific kinase inhibitor ) ; history solid organ transplant ; malignant disease diagnose within previous 5 year , exclude intraepithelial cervical neoplasia nonmelanoma skin cancer ; active central nervous system disease</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>